Quick Answer
Monte Rosa Therapeutics, Inc. reported Research And Development Expense of $141.50 million for the year ending 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +16.4% in Research And Development Expense from 2024 to 2025.
- This data is from Monte Rosa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $4.86 million | Q3 2020: $5.47 million | Q1 2021: $9.27 million | Q2 2021: $14.64 million | Q3 2021: $15.12 million | Q1 2022: $17.92 million | Q2 2022: $20.94 million | Q3 2022: $21.34 million | Q1 2023: $26.76 million | Q2 2023: $29.08 million | Q3 2023: $28.31 million | Q1 2024: $27.03 million | Q2 2024: $28.06 million | Q3 2024: $27.62 million | Q1 2025: $32.19 million | Q2 2025: $30.65 million | Q3 2025: $36.68 million.
- Over the full 6 years of available data (2020 to 2025), Monte Rosa Therapeutics, Inc.'s Research And Development Expense has grown by 489.5%.
- Historical annual values: Fiscal year 2025: $141.50 million | Fiscal year 2024: $121.56 million | Fiscal year 2023: $111.27 million | Fiscal year 2022: $85.06 million | Fiscal year 2021: $57.16 million | Fiscal year 2020: $24.01 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: